Severe cognitive impairment

The Carroll Center for the Blind Announces Strategic Partnership with Level Access to Advance Career Readiness for the Blind and Visually Impaired

Retrieved on: 
Thursday, December 15, 2022
Newton, Museum, Certification, Acquisition, WCAG, Severe cognitive impairment, ADA, Internet, Software, Partnership, DEI, Employment, ALL, Disability, History, Education, Section 508 Amendment to the Rehabilitation Act of 1973, AODA, CVAA, Organization, Online shopping, EU, Blind

NEWTON, Mass., Dec. 15, 2022 /PRNewswire/ -- The Carroll Center for the Blind—a pioneering and innovative vision rehabilitation and educational center for the blind and visually impaired of all ages, is pleased to announce its strategic partnership with Level Access—the trusted provider of enterprise digital accessibility solutions. Through this partnership, Level Access has committed to a multi-year grant to help fund The Carroll Center for the Blind's Screen Reader User Tester training program.

Key Points: 
  • Through this partnership, Level Access has committed to a multi-year grant to help fund The Carroll Center for the Blind's Screen Reader User Tester training program.
  • Just 44 percent of people who are blind or visually impaired are employed , compared to 79 percent of those without disabilities.
  • "Screen reader user testing plays a critical role in the work we're doing to make the web more inclusive.
  • Level Access and eSSENTIAL Accessibility, two leaders in the digital accessibility solution space, announced their merger in August 2022.

Stevie Wonder's We Are You Foundation Supports Wayfinder Family Services

Retrieved on: 
Wednesday, December 14, 2022
Optic nerve hypoplasia, Severe cognitive impairment, Optic nerve, KJLH, Disability, Disability in Canada, Sibling, Multimedia, Toy, Wayfinder

LOS ANGELES, Dec. 14, 2022 /PRNewswire/ -- Stevie Wonder's We Are You Foundation CEO Aundrae Russell presented Pierryae O'Neal with Wayfinder Family Services' annual Stevie Wonder Star Student Award during Wayfinder's holiday celebration on December 10th.

Key Points: 
  • LOS ANGELES, Dec. 14, 2022 /PRNewswire/ -- Stevie Wonder's We Are You Foundation CEO Aundrae Russell presented Pierryae O'Neal with Wayfinder Family Services' annual Stevie Wonder Star Student Award during Wayfinder's holiday celebration on December 10th.
  • After presenting the award to O'Neal, Russell presented a $50,000 donation to Wayfinder, "I am proud today to present this gift to Wayfinder Family Services from Stevie Wonder and the We Are You Foundation."
  • Thank you to Aundrae Russell and Jay Allen and Wayfinder for presenting me with this honor from the great Stevie Wonder," said O'Neal.
  • Wayfinder Family Services is the place to turn for people facing the greatest challenges.

Kellogg empowers blind consumers in U.S. with NaviLens technology on packaging

Retrieved on: 
Wednesday, December 14, 2022
Better Days, Frosted Flakes, Corn flakes, Heart, Kellogg's, Smartphone, Severe cognitive impairment, Food, Language, Name, Environment, University of Alicante, Partnership, ESG, Pop-Tarts, Climate, NYSE, Wrist, Disability, Snack, Breakfast, Food science, Eggo, Code, Food security, Multimedia, University, Centers for Disease Control and Prevention, Hearing, Motion, Corporate Affairs, QR, Cardboard, Online shopping, Pringles

BATTLE CREEK, Mich., Dec. 14, 2022 /PRNewswire/ -- Kellogg Company is changing the way the almost 12 million adults in the U.S. who are blind or have low vision* perform daily tasks, such as navigating a grocery store aisle or choosing one's cereal at breakfast. To help create a place at the table, Kellogg is incorporating innovative NaviLens technology into the packaging of four of its iconic cereal brands: Kellogg's Corn Flakes®, Special K Original®, Rice Krispies® and Crispix®.

Key Points: 
  • To help create a place at the table, Kellogg is incorporating innovative NaviLens technology into the packaging of four of its iconic cereal brands: Kellogg's Corn Flakes, Special K Original, Rice Krispies and Crispix.
  • "The heart of Kellogg's Better Days Promise ESG strategy is the advancement of sustainable and equitable access to food.
  • In addition to the cereal packaging, Kellogg has committed to incorporating NaviLens codes in all corporate facilities in the U.S. by the end of 2023, to make them more accessible and easier to navigate for blind and low-vision employees.
  • NaviLens is created by Neosistec, in collaboration with the Mobile Vision Research Lab at the University of Alicante.

LG NAMED TO DOW JONES SUSTAINABILITY WORLD INDEX

Retrieved on: 
Tuesday, December 13, 2022
Water, BSM, LG, Certification, Recycling, ESG, Home entertainment, Severe cognitive impairment, Electronics, International Organization (journal), Risk management, Disclosure, LG Corporation, News, Dow Jones, International Organization for Standardization, Television, LG Electronics, Fusion Global Business Solutions, USD, Carbon, Acquisition, Renewable energy, Management, MSCI, DJSI

ENGLEWOOD CLIFFS, N.J., Dec. 13, 2022 /PRNewswire/ -- LG Electronics has earned a place in the Dow Jones Sustainability World Index (DJSI World) for the 11th consecutive year, illustrating the company's ongoing leadership in responsible ESG management.

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., Dec. 13, 2022 /PRNewswire/ -- LG Electronics has earned a place in the Dow Jones Sustainability World Index (DJSI World) for the 11th consecutive year, illustrating the company's ongoing leadership in responsible ESG management.
  • LG scored well in all three areas of ESG management in this year's Index.
  • LG also has garnered Platinum status for the second straight year by independent, globally-trusted provider of business sustainability ratings, EcoVadis putting LG in the top one percent of all companies in terms of sustainability initiatives.
  • LG is a leading manufacturer of consumer and commercial products ranging from TVs, home appliances, air solutions, monitors, service robots, automotive components and its premium LG SIGNATURE and intelligent LG ThinQ brands are familiar names world over.

iFLYTEK Commits to Building a Barrier-free Future for People with Disabilities

Retrieved on: 
Friday, December 9, 2022
International, Accenture, Digital divide, Human voice, Severe cognitive impairment, Deafness, Hearing loss, AI, China Association for International Friendly Contact, Android, Artificial intelligence, Multimedia, Nature, IOS, White paper, Person

The iFLYREC system has provided over 47 million minutes of free transcription services for the hearing-impaired to date.

Key Points: 
  • The iFLYREC system has provided over 47 million minutes of free transcription services for the hearing-impaired to date.
  • iFLYTEK also developed new AI capabilities in the iFLYTEK Input Method to provide a free service for people with visual impairments.
  • iFLYTEK is committed to playing its part in using AI capabilities to build a barrier-free future for all.
  • About iFLYTEK iFLYTEK is one of the world's leading artificial intelligence (AI) and speech technology companies.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

Retrieved on: 
Friday, December 2, 2022
Plasma kallikrein, Sale, Capital commitment, SRS, Diabetic retinopathy, Agreement, DME, Capital, Euronext, Patient, Disclosure, Cayman, Severe cognitive impairment, Term Asset-Backed Securities Loan Facility, EUR, USD, Pharmaceutical industry, Security (finance), Limited

Negma Group has converted 322 convertible bonds in Oxurion resulting in a EUR 805,000 capital increase.

Key Points: 
  • Negma Group has converted 322 convertible bonds in Oxurion resulting in a EUR 805,000 capital increase.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 290,273,241, outstanding ordinary shares carrying voting rights (compared to 205,714,419 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.
  • Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.

Global Anti-reflective Coatings Market Report 2022: A $6.47 Billion Market by 2027 - Industry Trends, Analysis, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Chemicals, Plastics, Manufacturing, Lens, Urbanization, Telescope, COVID-19, Severe cognitive impairment, Electronics, Research, Dust, Humidity, Prevalence, Water, Temperature, Construction, R, Animal, Borosilicate glass, Paint, Potash, Growth

The "Anti-reflective Coatings Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-reflective Coatings Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global anti-reflective coatings market size reached US$ 4.41 Billion in 2021.
  • Anti-reflective coatings refer to the optical coatings that are formulated to minimize reflections from an optical surface.
  • What is the structure of the global anti-reflective coatings market and who are the key players?

Scotiabank and the CNIB announce $1.2 million community investment to help Canadians impacted by sight loss access employment opportunities

Retrieved on: 
Thursday, December 1, 2022
Organization, Toronto Stock Exchange, TSX, Conference, CNIB Foundation, Employment, CNIB, Bank, Partnership, Education, Chief sustainability officer, Severe cognitive impairment, BNS, Workforce, Come, Communication, Disability, New York Stock Exchange, Senior, NYSE, Scotiabank, Dream, Management, Medicine, Creative industries

Scotiabank's support for the CNIB will be directed towards the Come to Work Program , a national initiative that helps raise employment outcomes of working-age Canadians with visual impairments.

Key Points: 
  • Scotiabank's support for the CNIB will be directed towards the Come to Work Program , a national initiative that helps raise employment outcomes of working-age Canadians with visual impairments.
  • The program also educates corporate partners to better utilize assistive technology and accommodations to make workplaces more inclusive and increase recruitment of people with sight loss.
  • In Canada, the unemployment rate for people with sight loss is 14.5 per cent, three times higher than the general unemployment rate.
  • "We are proud to support the CNIB in its efforts to improve economic inclusion of people with sight loss and help them overcome barriers to employment."

Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5

Retrieved on: 
Thursday, December 1, 2022
Triangle Park (Quezon City), Severe cognitive impairment, Science, PARK, Food, Retina, LCA5, IND, Safety, Genetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, IPSC, Disease, Leber congenital amaurosis, Foundation Fighting Blindness, Retinal degeneration, LCA, AAV, RESEARCH, FDA, Pharmaceutical industry, Opus

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to retinal photoreceptors. Currently, there are no approved treatments for individuals with LCA5-related vision loss.

Key Points: 
  • OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to retinal photoreceptors.
  • This FDA clearance of our IND application for OPGx-001 for LCA5 marks a significant milestone for Opus, as our first program to enter the clinic, said Ben Yerxa, Ph.D., Chief Executive Officer of Opus.
  • OPGx-001 utilizes an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to photoreceptors in the retina.
  • Opus Genetics is a clinical-stage gene therapy company for inherited retinal diseases with a unique model and purpose.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022
Molecule, COVID-19, Neurodegeneration, RPE, Dementia, Severe cognitive impairment, Administration, Geographic atrophy, Laboratory, Potency (pharmacology), Food, DLB, Cell, Retinal, Risk, Therapy, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drusen, Macular degeneration, Retina, IPSC, Protein, Inflammation, Central nervous system, Disease, Cognition, AMD, POS, Alzheimer's disease, Lewy body, GA, Intellectual property, Phase II, Vance DeGeneres, Traffic barrier, Securities & Exchange Commission of Pakistan, Oxidative stress, Eye, Biology, Neuron, Dry, FDA, Pharmaceutical industry, Vaccine

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).